Figure 6: The effect of TrkB antagonist ANA-12 on the beneficial effects of EA.

(A-E) The effect of TrkB antagonist ANA-12 in naïve animals. (A,B) Morris water maze test. Mean time to locate the platform in the ANA-12 group was significantly reduced by EA treatment 3 days following the cessation of therapy. (C,D) Representative MBP-stained images of the corpus callosum and MBP histogram analysis. Data expressed as the mean (±SEM). ###P < 0.001, or $$P < 0.01 vs. EA group; *P < 0.05 vs. ANA-12 group. Scale bar = 400 μm. (E) Double immunofluorescent staining of BrdU and NG2 or CNPase in the corpus callosum. Data expressed as the mean (±SEM). ##P < 0.01, ###P < 0.001, $P < 0.05, and $$P < 0.01 vs. EA group; *P < 0.05 vs. ANA-12 group. (F,G) The effect of TrkB antagonist ANA-12 in BCAS + EA group. (F) Morris water maze test. ANA-12-treated BCAS + EA mice showed a significant increase in mean time to locate the platform compared to BCAS + EA mice. The box plot indicates the medians (black lines), the mean (white lines), 25th–75th percentiles (box), and 5th–95th percentiles (whiskers). (G) Double immunofluorescent staining of BrdU and NG2 or CNPase in the corpus callosum. Data expressed as the mean (±SEM). ##P < 0.01, ###P < 0.001 and *P < 0.05 vs. BCAS + EA group.